Duramed (DRMD) Synthetic Estrogen Product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: kevin kirkendall who started this subject	9/15/2000 12:20:00 AM
From: vestor	Read Replies (1) of 1837

Taken from DRMD web site...... Message from the CEO E. Thomas Arington I want to thank those shareholders who attended the 2000 Annual Shareholders’ Meeting and those who participated in the meeting by voting. More than 93 percent of Duramed’s shares were represented in person or by proxy. To see selected slides presented at the meeting, click here Just to recap the formal business conducted at the meeting: The vote to approve the 2000 Stock Option plan was in excess of 85 percent. The vote to ratify the choice of Ernst & Young LLP as independent public accountants for the year 2000 was in excess of 95 percent. And the vote to approve all proposed members of the company’s Board of Directors was in excess of 95 percent as well. I want to welcome Mr. Phillip J. Uhrhan to the Board of Directors. Mr. Uhrhan is Vice President, Finance at Solvay America, Inc. the parent of Solvay Pharmaceuticals, Inc. His industry experience and expertise will be an asset. I also want to announce the appointment of Jeffrey T. Arington as Duramed’s new President and Chief Operating Officer. Jeff was appointed to this new position by the Board at its meeting immediately following the Annual Shareholders’ Meeting. Jeff is a man of integrity and a team player. At the same time, he’s a decisive and a strong leader. As the new President and COO, Jeff will handle more day-to-day management and operations issues. This will permit me to dedicate more of my time and effort to strengthening relations with Wall Street, securing additional industry alliances, and focusing more intensely on corporate strategy and development. There is one other item I want to share with you. Duramed was issued another patent on July 4, 2000 for its TRI-AXIS™ drug delivery system. The patent is entitled, “Sustained Release Formulation Containing Three Different Types of Polymers and Tablets Therefrom.” This patent allows us to use TRI-AXIS technology in formulating future solid oral dose controlled-release products, both branded and multi-source, and will provide us patent protection for those products.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next